{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T19:54:14Z","timestamp":1757620454279,"version":"3.44.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T00:00:00Z","timestamp":1753660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T00:00:00Z","timestamp":1753660800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["U23A20419"],"award-info":[{"award-number":["U23A20419"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005270","name":"Fujian Provincial Department of Science and Technology","doi-asserted-by":"publisher","award":["2023Y9079"],"award-info":[{"award-number":["2023Y9079"]}],"id":[{"id":"10.13039\/501100005270","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The Talent Scientific Research Project of the First Affiliated Hospital of Fujian Medical University","award":["YJRC4415"],"award-info":[{"award-number":["YJRC4415"]}]},{"name":"Startup Fund for Scientific Research Project of Fujian Medical University","award":["2023QH2027"],"award-info":[{"award-number":["2023QH2027"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-025-06815-6","type":"journal-article","created":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T14:24:29Z","timestamp":1753712669000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["T cell receptor-like antibody specifically targets and eliminates cells infected with cytomegalovirus"],"prefix":"10.1186","volume":"23","author":[{"given":"Dabing","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caidong","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunda","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingjing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaqi","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinhua","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yangtao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ningshao","family":"Xia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Quan","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianda","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-5428-5622","authenticated-orcid":false,"given":"Ting","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,28]]},"reference":[{"key":"6815_CR1","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1182\/blood-2007-10-116582","volume":"111","author":"AH Goldstone","year":"2008","unstructured":"Goldstone AH, Richards SM, Lazarus HM, Tallman MS, Buck G, Fielding AK, Burnett AK, Chopra R, Wiernik PH, Foroni L, et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation\/maintenance chemotherapy in all patients: final results of the international ALL trial (MRC UKALL XII\/ECOG E2993). Blood. 2008;111:1827\u201333.","journal-title":"Blood"},{"key":"6815_CR2","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/bjh.13853","volume":"172","author":"SB Killick","year":"2016","unstructured":"Killick SB, Bown N, Cavenagh J, Dokal I, Foukaneli T, Hill A, Hillmen P, Ireland R, Kulasekararaj A, Mufti G, et al. Guidelines for the diagnosis and management of adult aplastic anaemia. Br J Haematol. 2016;172:187\u2013207.","journal-title":"Br J Haematol"},{"key":"6815_CR3","doi-asserted-by":"publisher","first-page":"101803","DOI":"10.1016\/j.trim.2023.101803","volume":"77","author":"SN Bayegi","year":"2023","unstructured":"Bayegi SN, Hamidieh AA, Behfar M, Saghazadeh A, Bozorgmehr M, Karamlou Y, Shekarabi M, Tajik N, Delbandi AA, Zavareh FT, et al. T helper 17 and regulatory T-cell profile and graft-versus-host disease after allogeneic hematopoietic stem cell transplantation in pediatric patients with beta-thalassemia. Transpl Immunol. 2023;77:101803.","journal-title":"Transpl Immunol"},{"key":"6815_CR4","doi-asserted-by":"publisher","first-page":"306","DOI":"10.7326\/M19-2511","volume":"172","author":"I Aldoss","year":"2020","unstructured":"Aldoss I, La Rosa C, Baden LR, Longmate J, Ariza-Heredia EJ, Rida WN, Lingaraju CR, Zhou Q, Martinez J, Kaltcheva T, et al. Poxvirus vectored cytomegalovirus vaccine to prevent cytomegalovirus viremia in transplant recipients: A phase 2, randomized clinical trial. Ann Intern Med. 2020;172:306\u201316.","journal-title":"Ann Intern Med"},{"key":"6815_CR5","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.bbmt.2015.08.028","volume":"22","author":"C de Koning","year":"2016","unstructured":"de Koning C, Plantinga M, Besseling P, Boelens JJ, Nierkens S. Immune reconstitution after allogeneic hematopoietic cell transplantation in children. Biol Blood Marrow Transpl. 2016;22:195\u2013206.","journal-title":"Biol Blood Marrow Transpl"},{"key":"6815_CR6","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1016\/S0140-6736(09)60237-3","volume":"373","author":"JL Ferrara","year":"2009","unstructured":"Ferrara JL, Levine JE, Reddy P, Holler E. Graft-versus-host disease. Lancet. 2009;373:1550\u201361.","journal-title":"Lancet"},{"key":"6815_CR7","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1016\/j.bbmt.2009.06.019","volume":"15","author":"M Tomblyn","year":"2009","unstructured":"Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz K, Storek J, Wingard JR, Young JA, Boeckh MJ. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transpl. 2009;15:1143\u2013238.","journal-title":"Biol Blood Marrow Transpl"},{"key":"6815_CR8","doi-asserted-by":"publisher","first-page":"e2034","DOI":"10.1002\/rmv.2034","volume":"29","author":"M Zuhair","year":"2019","unstructured":"Zuhair M, Smit GSA, Wallis G, Jabbar F, Smith C, Devleesschauwer B, Griffiths P. Estimation of the worldwide Seroprevalence of cytomegalovirus: A systematic review and meta-analysis. Rev Med Virol. 2019;29:e2034.","journal-title":"Rev Med Virol"},{"key":"6815_CR9","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.blre.2017.01.002","volume":"31","author":"ST Chan","year":"2017","unstructured":"Chan ST, Logan AC. The clinical impact of cytomegalovirus infection following allogeneic hematopoietic cell transplantation: why the quest for meaningful prophylaxis still matters. Blood Rev. 2017;31:173\u201383.","journal-title":"Blood Rev"},{"issue":"11","key":"6815_CR10","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.3390\/ijms20112666","volume":"20","author":"SY Cho","year":"2019","unstructured":"Cho SY, Lee DG, Kim HJ. Cytomegalovirus infections after hematopoietic stem cell transplantation: current status and future immunotherapy. Int J Mol Sci. 2019;20(11):2666.","journal-title":"Int J Mol Sci."},{"key":"6815_CR11","doi-asserted-by":"crossref","unstructured":"Heldman MR, Boeckh MJ, Limaye AP. Current and future strategies for the prevention and treatment of cytomegalovirus infections in transplantation. Clin Infect Dis. 2024; ciae535.","DOI":"10.1093\/cid\/ciae535"},{"key":"6815_CR12","doi-asserted-by":"publisher","first-page":"792","DOI":"10.4049\/jimmunol.1601992","volume":"199","author":"J Ogonek","year":"2017","unstructured":"Ogonek J, Verma K, Schultze-Florey C, Varanasi P, Luther S, Schweier P, K\u00fchnau W, G\u00f6hring G, Dammann E, Stadler M, et al. Characterization of High-Avidity Cytomegalovirus-Specific T cells with differential tetramer binding coappearing after allogeneic stem cell transplantation. J Immunol. 2017;199:792\u2013805.","journal-title":"J Immunol"},{"key":"6815_CR13","doi-asserted-by":"publisher","first-page":"e2558","DOI":"10.1002\/rmv.2558","volume":"34","author":"MR Taherian","year":"2024","unstructured":"Taherian MR, Azarbar P, Barkhordar M, Toufani S, Aliabadi LS, Bahri T, Ahmadvand M, Yaghmaie M, Daneshvar A, Vaezi M. Efficacy and safety of adoptive T-cell therapy in treating cytomegalovirus infections post-haematopoietic stem cell transplantation: A systematic review and meta-analysis. Rev Med Virol. 2024;34:e2558.","journal-title":"Rev Med Virol"},{"key":"6815_CR14","doi-asserted-by":"publisher","first-page":"181","DOI":"10.4049\/jimmunol.167.1.181","volume":"167","author":"JK Sandberg","year":"2001","unstructured":"Sandberg JK, Fast NM, Nixon DF. Functional heterogeneity of cytokines and cytolytic effector molecules in human CD8\u2009+\u2009T lymphocytes. J Immunol. 2001;167:181\u20137.","journal-title":"J Immunol"},{"key":"6815_CR15","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1074\/mcp.M114.042812","volume":"14","author":"M Bassani-Sternberg","year":"2015","unstructured":"Bassani-Sternberg M, Pletscher-Frankild S, Jensen LJ, Mann M. Mass spectrometry of human leukocyte antigen class I peptidomes reveals strong effects of protein abundance and turnover on antigen presentation. Mol Cell Proteom. 2015;14:658\u201373.","journal-title":"Mol Cell Proteom"},{"key":"6815_CR16","doi-asserted-by":"publisher","first-page":"5703","DOI":"10.4049\/jimmunol.165.10.5703","volume":"165","author":"K Polakova","year":"2000","unstructured":"Polakova K, Plaksin D, Chung DH, Belyakov IM, Berzofsky JA, Margulies DH. Antibodies directed against the MHC-I molecule H-2Dd complexed with an antigenic peptide: similarities to a T cell receptor with the same specificity. J Immunol. 2000;165:5703\u201312.","journal-title":"J Immunol"},{"key":"6815_CR17","doi-asserted-by":"publisher","first-page":"4187","DOI":"10.4049\/jimmunol.177.6.4187","volume":"177","author":"VP Wittman","year":"2006","unstructured":"Wittman VP, Woodburn D, Nguyen T, Neethling FA, Wright S, Weidanz JA. Antibody targeting to a class I MHC-peptide epitope promotes tumor cell death. J Immunol. 2006;177:4187\u201395.","journal-title":"J Immunol"},{"key":"6815_CR18","first-page":"3184","volume":"62","author":"A Lev","year":"2002","unstructured":"Lev A, Denkberg G, Cohen CJ, Tzukerman M, Skorecki KL, Chames P, Hoogenboom HR, Reiter Y. Isolation and characterization of human Recombinant antibodies endowed with the antigen-specific, major histocompatibility complex-restricted specificity of T cells directed toward the widely expressed tumor T-cell epitopes of the telomerase catalytic subunit. Cancer Res. 2002;62:3184\u201394.","journal-title":"Cancer Res"},{"key":"6815_CR19","doi-asserted-by":"publisher","first-page":"9421","DOI":"10.1073\/pnas.132285699","volume":"99","author":"G Denkberg","year":"2002","unstructured":"Denkberg G, Cohen CJ, Lev A, Chames P, Hoogenboom HR, Reiter Y. Direct visualization of distinct T cell epitopes derived from a melanoma tumor-associated antigen by using human Recombinant antibodies with MHC- restricted T cell receptor-like specificity. Proc Natl Acad Sci U S A. 2002;99:9421\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"6815_CR20","doi-asserted-by":"publisher","first-page":"194","DOI":"10.4049\/jimmunol.127.1.194","volume":"127","author":"DE Wylie","year":"1981","unstructured":"Wylie DE, Klinman NR. The murine B cell repertoire responsive to an influenza-infected syngeneic cell line. J Immunol. 1981;127:194\u20138.","journal-title":"J Immunol"},{"key":"6815_CR21","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1084\/jem.155.2.403","volume":"155","author":"DE Wylie","year":"1982","unstructured":"Wylie DE, Sherman LA, Klinman NR. Participation of the major histocompatibility complex in antibody recognition of viral antigens expressed on infected cells. J Exp Med. 1982;155:403\u201314.","journal-title":"J Exp Med"},{"key":"6815_CR22","doi-asserted-by":"publisher","first-page":"2387448","DOI":"10.1080\/22221751.2024.2387448","volume":"13","author":"Y Shi","year":"2024","unstructured":"Shi Y, Wang Z, Xu J, Niu W, Wu Y, Guo H, Shi J, Li Z, Fu B, Hong Y, et al. TCR-like bispecific antibodies toward eliminating infected hepatocytes in HBV mouse models. Emerg Microbes Infect. 2024;13:2387448.","journal-title":"Emerg Microbes Infect"},{"key":"6815_CR23","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1084\/jem.20050882","volume":"202","author":"AW Sylwester","year":"2005","unstructured":"Sylwester AW, Mitchell BL, Edgar JB, Taormina C, Pelte C, Ruchti F, Sleath PR, Grabstein KH, Hosken NA, Kern F, et al. Broadly targeted human cytomegalovirus-specific CD4\u2009+\u2009and CD8\u2009+\u2009T cells dominate the memory compartments of exposed subjects. J Exp Med. 2005;202:673\u201385.","journal-title":"J Exp Med"},{"key":"6815_CR24","doi-asserted-by":"publisher","first-page":"7569","DOI":"10.1128\/jvi.70.11.7569-7579.1996","volume":"70","author":"MR Wills","year":"1996","unstructured":"Wills MR, Carmichael AJ, Mynard K, Jin X, Weekes MP, Plachter B, Sissons JG. The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL. J Virol. 1996;70:7569\u201379.","journal-title":"J Virol"},{"key":"6815_CR25","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1128\/JVI.73.3.2099-2108.1999","volume":"73","author":"MP Weekes","year":"1999","unstructured":"Weekes MP, Wills MR, Mynard K, Carmichael AJ, Sissons JG. The memory cytotoxic T-lymphocyte (CTL) response to human cytomegalovirus infection contains individual peptide-specific CTL clones that have undergone extensive expansion in vivo. J Virol. 1999;73:2099\u2013108.","journal-title":"J Virol"},{"key":"6815_CR26","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1107\/S1744309109037890","volume":"65","author":"JB Reiser","year":"2009","unstructured":"Reiser JB, Legoux F, Machillot P, Debeaupuis E, Le Moullac-Vaydie B, Chouquet A, Saulquin X, Bonneville M, Housset D. Crystallization and preliminary X-ray crystallographic characterization of a public CMV-specific TCR in complex with its cognate antigen. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2009;65:1157\u201361.","journal-title":"Acta Crystallogr Sect F Struct Biol Cryst Commun"},{"issue":"5","key":"6815_CR27","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.3390\/ijms22052349","volume":"22","author":"SY Lee","year":"2021","unstructured":"Lee SY, Ko DH, Son MJ, Kim JA, Jung K, Kim YS. Affinity maturation of a T-Cell Receptor-Like antibody specific for a cytomegalovirus pp65-Derived peptide presented by HLA-A*02:01. Int J Mol Sci. 2021;22(5):2349.","journal-title":"Int J Mol Sci."},{"issue":"2","key":"6815_CR28","doi-asserted-by":"publisher","first-page":"2001031","DOI":"10.1002\/smtd.202001031","volume":"5","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Wang S, Wu Y, Hou W, Yuan L, Shen C, Wang J, Ye J, Zheng Q, Ma J, et al. Virus-Free and Live-Cell Visualizing SARS-CoV-2 Cell Entry for Studies of Neutralizing Antibodies and Compound Inhibitors. Small Methods. 2021;5(2):2001031.","journal-title":"Small Methods."},{"issue":"9","key":"6815_CR29","doi-asserted-by":"publisher","first-page":"100856","DOI":"10.1016\/j.crmeth.2024.100856","volume":"4","author":"J Chen","year":"2024","unstructured":"Chen J, Huang Z, Xiao J, Du S, Bu Q, Guo H, Ye J, Chen S, Gao J, Li Z, et al. A quadri-fluorescence SARS-CoV-2 pseudovirus system for efficient antigenic characterization of multiple circulating variants. Cell Rep Methods. 2024;4(9):100856.","journal-title":"Cell Rep Methods."},{"key":"6815_CR30","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1093\/cid\/ciy696","volume":"68","author":"RF Chemaly","year":"2019","unstructured":"Chemaly RF, Chou S, Einsele H, Griffiths P, Avery R, Razonable RR, Mullane KM, Kotton C, Lundgren J, Komatsu TE, et al. Definitions of resistant and refractory cytomegalovirus infection and disease in transplant recipients for use in clinical trials. Clin Infect Dis. 2019;68:1420\u20136.","journal-title":"Clin Infect Dis"},{"key":"6815_CR31","doi-asserted-by":"publisher","first-page":"100787","DOI":"10.1016\/j.eclinm.2021.100787","volume":"33","author":"P Ljungman","year":"2021","unstructured":"Ljungman P, Bermudez A, Logan AC, Kharfan-Dabaja MA, Chevallier P, Martino R, Wulf G, Selleslag D, Kakihana K, Langston A, et al. A randomised, placebo-controlled phase 3 study to evaluate the efficacy and safety of ASP0113, a DNA-based CMV vaccine, in seropositive allogeneic Haematopoietic cell transplant recipients. EClinicalMedicine. 2021;33:100787.","journal-title":"EClinicalMedicine"},{"key":"6815_CR32","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1016\/S0140-6736(11)60136-0","volume":"377","author":"PD Griffiths","year":"2011","unstructured":"Griffiths PD, Stanton A, McCarrell E, Smith C, Osman M, Harber M, Davenport A, Jones G, Wheeler DC, O\u2019Beirne J, et al. Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial. Lancet. 2011;377:1256\u201363.","journal-title":"Lancet"},{"key":"6815_CR33","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/S0140-6736(84)90930-9","volume":"1","author":"SA Plotkin","year":"1984","unstructured":"Plotkin SA, Smiley ML, Friedman HM, Starr SE, Fleisher GR, Wlodaver C, Dafoe DC, Friedman AD, Grossman RA, Barker CF. Towne-vaccine-induced prevention of cytomegalovirus disease after renal transplants. Lancet. 1984;1:528\u201330.","journal-title":"Lancet"},{"key":"6815_CR34","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1086\/319680","volume":"183","author":"K Berencsi","year":"2001","unstructured":"Berencsi K, Gyulai Z, G\u00f6ncz\u00f6l E, Pincus S, Cox WI, Michelson S, Kari L, Meric C, Cadoz M, Zahradnik J, et al. A Canarypox vector-expressing cytomegalovirus (CMV) phosphoprotein 65 induces long-lasting cytotoxic T cell responses in human CMV-seronegative subjects. J Infect Dis. 2001;183:1171\u20139.","journal-title":"J Infect Dis"},{"key":"6815_CR35","first-page":"1994","volume":"109","author":"R Nakamura","year":"2024","unstructured":"Nakamura R, La Rosa C, Yang D, Hill JA, Rashidi A, Choe H, Zhou Q, Lingaraju CR, Kaltcheva T, Longmate J, et al. A phase II randomized, placebo-controlled, multicenter trial to evaluate the efficacy of cytomegalovirus PepVax vaccine in preventing cytomegalovirus reactivation and disease after allogeneic hematopoietic stem cell transplant. Haematologica. 2024;109:1994\u20139.","journal-title":"Haematologica"},{"key":"6815_CR36","doi-asserted-by":"crossref","unstructured":"Ci\u00e1urriz M, Beloki L, Zabalza A, Bandr\u00e9s E, Mansilla C, P\u00e9rez-Valderrama E, Lach\u00e9n M, Rodr\u00edguez-Calvillo M, Ram\u00edrez N, Olavarr\u00eda E. Functional specific-T-cell expansion after first cytomegalovirus reactivation predicts viremia control in allogeneic hematopoietic stem cell transplant recipients. Transpl Infect Dis. 2017;19(6).","DOI":"10.1111\/tid.12778"},{"key":"6815_CR37","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1093\/cid\/ciz1209","volume":"71","author":"M Jarque","year":"2020","unstructured":"Jarque M, Crespo E, Melilli E, Guti\u00e9rrez A, Moreso F, Guirado L, Revuelta I, Montero N, Torras J, Riera L, et al. Cellular immunity to predict the risk of cytomegalovirus infection in kidney transplantation: A prospective, interventional, multicenter clinical trial. Clin Infect Dis. 2020;71:2375\u201385.","journal-title":"Clin Infect Dis"},{"key":"6815_CR38","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s13045-019-0701-1","volume":"12","author":"T Kaeuferle","year":"2019","unstructured":"Kaeuferle T, Krauss R, Blaeschke F, Willier S, Feuchtinger T. Strategies of adoptive T -cell transfer to treat refractory viral infections post allogeneic stem cell transplantation. J Hematol Oncol. 2019;12:13.","journal-title":"J Hematol Oncol"},{"key":"6815_CR39","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1093\/cid\/ciz368","volume":"70","author":"XY Zhao","year":"2020","unstructured":"Zhao XY, Pei XY, Chang YJ, Yu XX, Xu LP, Wang Y, Zhang XH, Liu KY, Huang XJ. First-line therapy with Donor-derived human cytomegalovirus (HCMV)-specific T cells reduces persistent HCMV infection by promoting antiviral immunity after allogenic stem cell transplantation. Clin Infect Dis. 2020;70:1429\u201337.","journal-title":"Clin Infect Dis"},{"key":"6815_CR40","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1093\/cid\/ciy549","volume":"68","author":"C Smith","year":"2019","unstructured":"Smith C, Beagley L, Rehan S, Neller MA, Crooks P, Solomon M, Holmes-Liew CL, Holmes M, McKenzie SC, Hopkins P, et al. Autologous adoptive T-cell therapy for recurrent or Drug-resistant cytomegalovirus complications in solid organ transplant recipients: A Single-arm Open-label phase I clinical trial. Clin Infect Dis. 2019;68:632\u201340.","journal-title":"Clin Infect Dis"},{"key":"6815_CR41","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1093\/infdis\/jix357","volume":"216","author":"XY Pei","year":"2017","unstructured":"Pei XY, Zhao XY, Chang YJ, Liu J, Xu LP, Wang Y, Zhang XH, Han W, Chen YH, Huang XJ. Cytomegalovirus-Specific T-Cell transfer for refractory cytomegalovirus infection after haploidentical stem cell transplantation: the quantitative and qualitative immune recovery for cytomegalovirus. J Infect Dis. 2017;216:945\u201356.","journal-title":"J Infect Dis"},{"issue":"10","key":"6815_CR42","doi-asserted-by":"publisher","first-page":"e165476","DOI":"10.1172\/JCI165476","volume":"133","author":"SE Prockop","year":"2023","unstructured":"Prockop SE, Hasan A, Doubrovina E, Dahi PB, Rodriguez-Sanchez I, Curry M, Mauguen A, Papanicolaou GA, Su Y, Yao J et al. Third-party cytomegalovirus-specific T cells improved survival in refractory cytomegalovirus viremia after hematopoietic transplant. J Clin Invest. 2023;133(10):e165476.","journal-title":"J Clin Invest."},{"key":"6815_CR43","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1182\/bloodadvances.2017010223","volume":"1","author":"B Withers","year":"2017","unstructured":"Withers B, Blyth E, Clancy LE, Yong A, Fraser C, Burgess J, Simms R, Brown R, Kliman D, Dubosq MC, et al. Long-term control of recurrent or refractory viral infections after allogeneic HSCT with third-party virus-specific T cells. Blood Adv. 2017;1:2193\u2013205.","journal-title":"Blood Adv"},{"key":"6815_CR44","doi-asserted-by":"publisher","first-page":"4949","DOI":"10.1182\/bloodadvances.2022007103","volume":"6","author":"W Jiang","year":"2022","unstructured":"Jiang W, Clancy LE, Avdic S, Sutrave G, Street J, Simms R, McGuire HM, Patrick E, Chan AS, McCaughan G, et al. Third-party CMV- and EBV-specific T-cells for first viral reactivation after allogeneic stem cell transplant. Blood Adv. 2022;6:4949\u201366.","journal-title":"Blood Adv"},{"key":"6815_CR45","doi-asserted-by":"publisher","first-page":"3745","DOI":"10.1182\/blood-2012-08-448977","volume":"121","author":"E Blyth","year":"2013","unstructured":"Blyth E, Clancy L, Simms R, Ma CK, Burgess J, Deo S, Byth K, Dubosq MC, Shaw PJ, Micklethwaite KP, Gottlieb DJ. Donor-derived CMV-specific T cells reduce the requirement for CMV-directed pharmacotherapy after allogeneic stem cell transplantation. Blood. 2013;121:3745\u201358.","journal-title":"Blood"},{"key":"6815_CR46","doi-asserted-by":"publisher","first-page":"3258","DOI":"10.1038\/s41467-024-47057-2","volume":"15","author":"MD Keller","year":"2024","unstructured":"Keller MD, Hanley PJ, Chi YY, Aguayo-Hiraldo P, Dvorak CC, Verneris MR, Kohn DB, Pai SY, D\u00e1vila Salda\u00f1a BJ, Hanisch B, et al. Antiviral cellular therapy for enhancing T-cell reconstitution before or after hematopoietic stem cell transplantation (ACES): a two-arm, open label phase II interventional trial of pediatric patients with risk factor assessment. Nat Commun. 2024;15:3258.","journal-title":"Nat Commun"},{"key":"6815_CR47","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1016\/j.ajt.2024.04.009","volume":"24","author":"R Khoury","year":"2024","unstructured":"Khoury R, Grimley MS, Nelson AS, Leemhuis T, Cancelas JA, Cook E, Wang Y, Heyenbruch D, Bollard CM, Keller MD, et al. Third-party virus-specific T cells for the treatment of double-stranded DNA viral reactivation and posttransplant lymphoproliferative disease after solid organ transplant. Am J Transpl. 2024;24:1634\u201343.","journal-title":"Am J Transpl"},{"key":"6815_CR48","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.jtct.2023.01.027","volume":"29","author":"TJ Galletta","year":"2023","unstructured":"Galletta TJ, Lane A, Lutzko C, Leemhuis T, Cancelas JA, Khoury R, Wang YM, Hanley PJ, Keller MD, Bollard CM, et al. Third-Party and Patient-Specific Donor-Derived Virus-Specific T cells demonstrate similar efficacy and safety for management of viral infections after hematopoietic stem cell transplantation in children and young adults. Transpl Cell Ther. 2023;29:305\u201310.","journal-title":"Transpl Cell Ther"},{"key":"6815_CR49","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1158\/1078-0432.CCR-22-2415","volume":"29","author":"T Pfeiffer","year":"2023","unstructured":"Pfeiffer T, Tzannou I, Wu M, Ramos C, Sasa G, Martinez C, Lulla P, Krance RA, Scherer L, Ruderfer D, et al. Posoleucel, an allogeneic, Off-the-Shelf Multivirus-Specific T-Cell therapy, for the treatment of refractory viral infections in the Post-HCT setting. Clin Cancer Res. 2023;29:324\u201330.","journal-title":"Clin Cancer Res"},{"key":"6815_CR50","doi-asserted-by":"publisher","first-page":"4740","DOI":"10.1182\/bloodadvances.2023011562","volume":"8","author":"SS Dadwal","year":"2024","unstructured":"Dadwal SS, Bansal R, Schuster MW, Yared JA, Myers GD, Matzko M, Adnan S, McNeel D, Ma J, Gilmore SA, et al. Final outcomes from a phase 2 trial of Posoleucel in allogeneic hematopoietic cell transplant recipients. Blood Adv. 2024;8:4740\u201350.","journal-title":"Blood Adv"},{"issue":"1","key":"6815_CR51","doi-asserted-by":"publisher","first-page":"e00043-19","DOI":"10.1128\/CMR.00043-19","volume":"34","author":"AP Limaye","year":"2020","unstructured":"Limaye AP, Babu TM, Boeckh M. Progress and challenges in the prevention, diagnosis, and management of cytomegalovirus infection in transplantation. Clin Microbiol Rev. 2020;34(1):e00043-19.","journal-title":"Clin Microbiol Rev."},{"key":"6815_CR52","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/S1083-8791(01)80005-7","volume":"7","author":"M Boeckh","year":"2001","unstructured":"Boeckh M, Bowden RA, Storer B, Chao NJ, Spielberger R, Tierney DK, Gallez-Hawkins G, Cunningham T, Blume KG, Levitt D, Zaia JA. Randomized, placebo-controlled, double-blind study of a cytomegalovirus-specific monoclonal antibody (MSL-109) for prevention of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transpl. 2001;7:343\u201351.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"4","key":"6815_CR53","doi-asserted-by":"publisher","first-page":"e02467-19","DOI":"10.1128\/AAC.02467-19","volume":"64","author":"J Maertens","year":"2020","unstructured":"Maertens J, Logan AC, Jang J, Long G, Tang JL, Hwang WYK, Koh LP, Chemaly R, Gerbitz A, Winkler J et al. Phase 2 study of Anti-Human cytomegalovirus monoclonal antibodies for prophylaxis in hematopoietic cell transplantation. Antimicrob Agents Chemother. 2020;64(4):e02467-19.","journal-title":"Antimicrob Agents Chemother."},{"issue":"2","key":"6815_CR54","doi-asserted-by":"publisher","first-page":"e01794-16","DOI":"10.1128\/AAC.01794-16","volume":"61","author":"JH Ishida","year":"2017","unstructured":"Ishida JH, Patel A, Mehta AK, Gatault P, McBride JM, Burgess T, Derby MA, Snydman DR, Emu B, Feierbach B et al. Phase 2 randomized, Double-Blind, Placebo-Controlled trial of RG7667, a combination monoclonal antibody, for prevention of cytomegalovirus infection in High-Risk kidney transplant recipients. Antimicrob Agents Chemother. 2017;61(2):e01794-16.","journal-title":"Antimicrob Agents Chemother."},{"key":"6815_CR55","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1080\/14712598.2016.1176138","volume":"16","author":"AY Chang","year":"2016","unstructured":"Chang AY, Gejman RS, Brea EJ, Oh CY, Mathias MD, Pankov D, Casey E, Dao T, Scheinberg DA. Opportunities and challenges for TCR mimic antibodies in cancer therapy. Expert Opin Biol Ther. 2016;16:979\u201387.","journal-title":"Expert Opin Biol Ther"},{"key":"6815_CR56","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.jmb.2015.12.002","volume":"428","author":"N Ataie","year":"2016","unstructured":"Ataie N, Xiang J, Cheng N, Brea EJ, Lu W, Scheinberg DA, Liu C, Ng HL. Structure of a TCR-Mimic antibody with target predicts pharmacogenetics. J Mol Biol. 2016;428:194\u2013205.","journal-title":"J Mol Biol"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-06815-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-025-06815-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-06815-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T07:02:23Z","timestamp":1757314943000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-025-06815-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,28]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6815"],"URL":"https:\/\/doi.org\/10.1186\/s12967-025-06815-6","relation":{},"ISSN":["1479-5876"],"issn-type":[{"type":"electronic","value":"1479-5876"}],"subject":[],"published":{"date-parts":[[2025,7,28]]},"assertion":[{"value":"21 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Medical Ethics Committee of The First Affiliated Hospital, Fujian Medical University ([2015]084\u2009\u2212\u20092). Informed consent was obtained from all patients, and animal experiments were conducted with the approval of the Institutional Animal Care and Use Committee of Fujian Medical University (FJMU IACUC 2021\u2009\u2212\u20090420).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors acknowledge and consent to the paper\u2019s content and are included as co-authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"846"}}